SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of DBV Technologies S.A. (DBVT)

Author's Avatar
Dec 27, 2018
Article's Main Image

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers DBV Technologies S.A. ("DBV Technologies" or the "Company") ( DBVT). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/dbvt.

The investigation concerns whether DBV Technologies and certain of its officers and/or directors have violated federal securities laws.

On October 22, 2018, the Company announced the submission of a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age. When the Company announced the submission of the BLA Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies, stated that "This submission represents a significant step forward for those families living with peanut allergy. We are thankful for the patients, investigators and DBV employees' efforts in making this milestone possible…We have been developing Viaskin Peanut for over 10 years, with over 1,000 patients studied in our clinical trials, and we are excited about the possibility of helping patients suffering from peanut allergy."

On December 19, 2018, DBV Technologies revealed that its BLA for Viaskin Peanut had been voluntarily withdrawn following discussions with the FDA. The Company stated, "although the agency did not reference any medical or clinical questions with the submission of Viaskin Peanut, the FDA did communicate that the level of detail with regards to data on manufacturing and quality controls was insufficient in the BLA." On this news shares of DBV Technologies fell $8.39 or nearly 60% to close at $5.76 on December 20, 2018.

If you are aware of any facts relating to this investigation, or purchased DBV Technologies shares, you can assist this investigation by visiting the firm’s site: bgandg.com/dbv. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

ti?nf=NzQ3MDc1NyMyNjY1MjQzIzIwMTc2OTA=